Video

Mike Fazio: Practices Are Happier With PP4 Results in the OCM

There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.

There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.

Transcript

Results for performance period 4 of the Oncology Care Model just came out; what are the initial takeaways?

Practices that consistently have performed well continued to perform well. Practices that were trending in the right direction, but maybe haven’t made savings, a few of our practices have made savings, they made it over that finish line, and we’ve set that expectation that that is likely to happen given the good work that they were doing, and they’re seeing those results. And practices that haven’t performed well consistently, no surprise, didn’t get a very good report card with this reconciliation.

About half of our practices earned a PBP [performance-based payment] by this period, which is a performance period 4. That’s an increase in what we saw since performance period 3, which was about a third of our customer base earned a savings payment.

So, that was exciting news. I think overall, practices are happy with the results. I’m seeing a lot of smiling faces based on those results here, at [the Quality Cancer Care Alliance Fall 2019 Leadership Summit], which is great. But they’re a high-performing group, so they’re biased in that way, as they’re more progressive and stronger performing than some of the other practices that we work with. But good results overall, I think.

Related Videos
Screenshot of Adam Colborn, JD during an interview
Ruben Mesa, MD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with Adam Colborn, JD
Screenshot of Stephanie Hsia, PharmD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Interview screenshot with Megan Ehret, PharmD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo